American Heart Association
Scientific Sessions

1989
New Orleans, Louisiana
November 13-16

1990
Dallas, Texas
November 12-15

1991
Anaheim, California
November 18-21

1992
New Orleans, Louisiana
November 9-12
12th Annual
INTENSIVE CLINICAL
NEUROLOGY COURSE
(I.C.N.C.)

A PROBLEM ORIENTED APPROACH TO
NEUROLOGY FOR FAMILY PHYSICIANS,
EMERGENCY PHYSICIANS, INTERNISTS AND
PSYCHIATRISTS BY LAWRENCE P. LEVITT, M.D.
AND HOWARD L. WEINER, M.D., AUTHORS OF
NEUROLOGY FOR THE
HOUSE OFFICER

Guest Lecturer:
Martin A. Samuels, M.D.

MARCH 31, APRIL 1, 2, 1989
GRAND HYATT OF NEW YORK

Approved for 15 hours Category 1, AMA, Physicians
Recognition Award; and 15 prescribed hours from the
American Academy of Family Practice, 15 hrs. from
American College of Emergency Physicians and 15
hrs. from American Osteopathic Association

FEE: $370 RESIDENTS OR FELLOWS: $270

FOR REGISTRATION OR
FURTHER INFORMATION CONTACT:
L. P. LEVITT, M.D., COURSE DIRECTOR
1210 S. Cedar Crest Blvd., Allentown, PA 18103
(215) 776-8420

NAME: ____________________________
SPECIALTY: ____________________________
ADDRESS: ____________________________
________________________ TELEPHONE: ____________
□ PLEASE SEND ME ADDITIONAL INFORMATION RE: I.C.N.C.
□ ENCLOSED IS MY CHECK; PLEASE SEND REGISTRATION DETAILS

STROKE FELLOWSHIP: The Yale Stroke Program
has positions for fellowship beginning July 1989. The
training program will combine patient care and clinical
research responsibilities, and will include in-depth
training in the diagnosis, physiology, and manage-
ment of stroke. The fellow will participate in on-going
clinical trials for stroke management including calci-
um channel blockers, gangliosides, thrombolytic
agents, and carotid surgery. Imaging protocols in-
clude MRI, SPECT, CT, MR spectroscopy, and trans-
cranial Doppler sonology. PET and Xenon cerebral
blood flow laboratories are in the planning stages.
Independent research projects will be developed as
part of the program. Interdepartmental projects with
neurosurgery, cardiology, epidemiology, public health,
biophysics, immunology, hematology, radiology, ul-
trasound, and nuclear medicine are easily arranged
and encouraged. Although principally a clinical fel-
lowship, there will also be opportunities for exposure
to cellular and animal models of ischemia. There will
be extensive training in the theory and design of
computerized clinical databases. The candidate may
also apply for additional years of training in Epide-
miology as a Robert Wood Johnson Clinical Scholar.
Please send CV and inquiries to:
Lawrence M. Brass, M.D., Yale Stroke Program,
Department of Neurology LCI-700, Yale University
School of Medicine, 333 Cedar St., New Haven, CT
06510. Yale University is an Equal Opportunity/  
Affirmative Action Employer.

This is the most
sophisticated weapon
in the war
against heart disease.

THE AMERICAN
HEART ASSOCIATION
PHARMACEUTICAL
ROUNDTABLE

FOUNDING MEMBERS
Bristol-Myers Company
CIBA-GEIGY Corporation
Genentech, Inc.
Sandoz Pharmaceuticals
Corporation
Squibb Corporation
Winthrop Pharmaceuticals
Division of Sterling Drugs, Inc.
Wyeth-Ayerst Laboratories

REGULAR MEMBER
Boehringer Ingelheim
Pharmaceuticals, Inc.
Cation transport, which may be helpful in predicting which normotensive individuals are at increased risk for developing hypertension, was a focus of the Workshop on Cation Transport and Natriuretic Factors held May 13-14, 1985, in Cambridge, Massachusetts, and sponsored by the National Heart, Lung, and Blood Institute. Updated versions of the papers presented and discussed at the workshop include the influence of atrial natriuretic factor on sodium-potassium-chloride cotransport in vascular smooth muscle cells and the identification, purification, and role of atrial natriuretic factor in blood pressure regulation and in hypertension. Supplement to Hypertension, November 1987. Hypertension Monograph No. 3, soft cover, 130 pp. ISSN 0194-911X ISBN 0-87493-652-7.

Order No. 73-1163 $12.00

The Proceedings of the 7th Scientific Meeting of the Inter-American Society
Edgar Haber (ed)
More than 50 years ago investigators from the United States and Argentina simultaneously and independently discovered angiotensin, one of the most significant contributions to the study of hypertension. The Inter-American Society of Hypertension, created 10 years ago, has held a scientific conference every two years to foster communication among scientists in the fields of basic and clinical hypertension research. This supplement to Hypertension contains the proceedings of the seventh scientific meeting held May 10-13, 1987, in Buenos Aires, Argentina. Included are state-of-the-art lectures, special lectures, and a satellite symposium on calcium antagonists, as well as original articles on atrial natriuretic factor immunoreactivity in human fetal lung tissue and perfusates, contractile response of spontaneously hypertensive rat caudal artery to phorbol esters, and the role of vasopressin in blood pressure maintenance in diabetic orthostatic hypotension. Supplement to Hypertension, February 1988. Hypertension Monograph No. 4, soft cover, 235 pp. ISSN 0194-911X ISBN 0-87493-653-5.

Order No. 73-2001 $16.80

Michael J. Horan, Lot B. Page (eds)
Over the past 20 years, the efficacy of drug treatment for hypertension in reducing the incidence of death and major cardiovascular morbid events has been clearly demonstrated. At this National Institutes of Health Workshop held April 28-29, 1986, in Bethesda, Maryland, facets in the management of hypertension that contribute to treatment failure or to clinical morbidity even when blood pressure is controlled were critically examined. This supplement to Hypertension contains the proceedings from that workshop and covers such topics as phenylpropanolamine and other over-the-counter vasoactive compounds, classification of resistant hypertension, and blood pressure monitoring outside the office for the evaluation of patients with resistant hypertension. Supplement to Hypertension, March 1988. Hypertension Monograph No. 5, soft cover, 106 pp. ISSN 0194-911X ISBN 0-87493-654-3.

Order No. 73-2002 $12.00
### Hypertension Research: Echocardiography in the Measurement of Left Ventricular Wall Mass

Philip R. Liebson, Richard B. Devereux, Michael J. Horan (eds)

In September 1984, the National Heart, Lung, and Blood Institute sponsored a conference on the use of echocardiography in hypertension research. This supplement to the February 1987 issue of *Hypertension* contains proceedings of the conference. Included are papers on reproducibility of echocardiographic measurements, standardization in measurement of wall mass by M-mode and two-dimensional echocardiography, measurement of left ventricular wall mass in pediatric patients, echocardiography in epidemiology, future directions in the use of echocardiography, and recommendations concerning its use in hypertension and general population research. Hypertension Monograph No. 1, soft cover, 104 pp. ISBN 0-87493-650-0.

Order No. 73-114-A $6.00

### The Heart and Coronary Vessels in Hypertension

Robert C Tarazi (ed)

Relationships between the heart, coronary vessels, and hypertension are the theme of this monograph, which is a supplement to the January 1987 issue of *Circulation*. Topics include a critical review of coronary reserve, the effects of aging and hypertension on the myocardium, reversal of cardiac hypertrophy as a goal of antihypertensive therapy, and evidence of the existence of renin in the heart. Robert C Tarazi reviewed and edited the manuscripts contained in this volume, which was published one year after his death. Circulation Monograph No. 1, soft cover, 179 pp. ISBN 0-87493-250-5.

Order No. 73-1150 $7.20

### Proceedings of the Council for High Blood Pressure Research, 1986

Michael J. Dunn (ed)

For the past three years, the fall conference of the council for High Blood Pressure Research has grown considerably. Not only has the number of submitted manuscripts increased but also the diversity of topics, indicating the high scientific quality of basic and clinical work in hypertension research. The 1986 proceedings covered such topics as the contribution of bradykinin in the maintenance of normal blood pressure, the role of α1- and α2-adrenergic receptors in the human hypertensive kidney, and the possible influence of the Multicenter Clinical Trials on consumer education. Supplement to *Hypertension*, June 1987. Hypertension Monograph No. 2, soft cover, 214 pp. ISSN 0194-911X ISBN 0-87493-651-9.

Order No. 73-1155 $8.40
Money can't buy it. But a changed life-style can go a long way toward a healthier future.

Smart living includes eating right—the kinds of delicious, low-fat, low-cholesterol foods contained in the American Heart Association Cookbook. It's designed to help health-conscious people prepare foods that will help them maintain a reasonable weight, reduce the amount of fat and cholesterol in the diet, and cut salt intake.

In this fourth edition of the AHA Cookbook, you'll find the latest scientific evidence on the relationship between diet and heart health. You'll also find:

- Dietary guidelines for children—how you can start them off right with low-fat, low-cholesterol foods and still satisfy the needs of the "fast food" generation.
- A complete guide to restaurant dining
- A totally revised fat and cholesterol chart outlining the fat content of common foods
- Expanded information on the basics of microwave cookery

For a blend of good taste and good health, recommend the American Heart Association Cookbook to your patients.
Prevent the event

PLATELET ADHESION INHIBITOR

Persantine®
(dipyridamole)
Tablets of 25, 50 and 75 mg

Prevents thromboembolic events when used in combination with coumarin anticoagulants in cardiac valve replacement

Brief Summary of Prescribing Information

CONTRAINDICATIONS None known.

PRECAUTIONS General Persantine® (dipyridamole USP) should be used with caution in patients with hypotension since it can produce peripheral vasodilation.

Carcinogenesis, Impairment of Fertility In a 111 week oral study in mice and in a 129-142 week orally in rats, Persantine produced no significant carcinogenic effects at doses of 8, 25, and 75 mg/kg (1, 3.4, and 6.4 times the maximum recommended daily human dose) in combination with Persantine studies with Persantine. Impaired fertility in rats at doses of 80 to 400 times the maximum recommended human dose. A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 155 times the maximum recommended human dose.

Teratogenic Effects PREGNANCY CATEGORY B

Reproduction studies have been performed in mice and rats at doses up to 125 mg/kg (15.6 times the maximum recommended daily human dose) and rabbits at doses up to 20 mg/kg and have revealed no evidence of harm to the fetus due to Persantine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers As dipyridamole is excreted in human milk, caution should be exercised when Persantine® (dipyridamole USP) is administered to a nursing woman.

Pediatric Use Safety and effectiveness in children have not been established.

Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication.

When Persantine® (dipyridamole USP) was administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone.

Persantine® (dipyridamole USP) is available as coated tablets of 25 mg, 50 mg and 75 mg in the following package sizes:

25 and 50 mg Tablets: Bottles of 100 and 1000, unit dose of 100.

75 mg Tablets: Bottles of 100 and 500, unit dose of 100.

Consult package insert before prescribing.

PE-4024AR

Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877